Cipla receives final approval for generic version of GlaxoSmithKline’s IMITREX® (Sumatriptan Nasal Spray, 20 mg) Kumar Jeetendra | March 2, 2021 Mumbai, India, March 02, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ hereinafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA). Cipla’s Sumatriptan Nasal Spray USP, 20 mg …
